Clinical Trials
14 trialsNCT01545141 2023-10-27
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT00019474 2018-09-14
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
Montefiore Medical Center
Phase 2 Completed
NCT01681446 2018-06-01
Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression
Fudan University
Phase 3 Unknown
NCT00262951 2017-12-28
Chemoradiation in Locally Advanced Pancreatic Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00660270 2013-04-23
Chemotherapy and Radiation Following Pancreatic Surgery
Washington University School of Medicine
Phase 2 Completed
NCT00838968 2012-08-23
The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma
Fudan University
Phase NA Withdrawn
NCT00004897 2012-06-12
Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
Northwestern University
Phase 2 Terminated
NCT00068575 2012-02-15
Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00002506 2011-05-12
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer
Hoag Memorial Hospital Presbyterian
Phase 2 Completed
NCT00178698 2011-03-03
FR-WB-TT/che
The University of Texas Health Science Center, Houston
Phase 2 Unknown
NCT00178763 2011-03-03
FR-WB-TT
The University of Texas Health Science Center, Houston
Phase 2 Unknown
NCT00761241 2010-05-26
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
Benaroya Research Institute
Phase 2 Completed
NCT01060501 2010-02-02
FOGT1
University of Ulm
Phase 3 Completed
NCT00250796 2010-01-07
Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma
University of New Mexico
Phase 2 Completed